GlassScriptPhysician profile
Amanda C Dudley
NPI 1023764081
$1,121.50
in general payments reported to CMS, 2019-2025
25 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $461 · 2023: $289 · 2024: $268 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $282.42 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $74.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.43 | 2022 | |
| Insulet Corporation | $67.95 | 2023-2024 | Omnipod |
| Novo Nordisk INC | $67.83 | 2022-2023 | Ozempic, Rybelsus |
| Medtronic, INC. | $58.22 | 2023-2025 | Intellis Adaptivestim |
| Boston Scientific Corporation | $57.36 | 2023-2024 | Spectra Wavewriter, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $57.07 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.25 | 2022 | |
| Lilly USA, LLC | $43.22 | 2022-2023 | Mounjaro |
| Amgen INC. | $42.69 | 2022-2024 | Otezla, Repatha, Prolia |
| Amarin Pharma, INC. | $27.69 | 2022 | |
| Ascensia Diabetes Care US INC. | $24.36 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.05 | 2022 | |
| Axsome Therapeutics, INC. | $23.62 | 2024 | Sunosi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.38 | 2022 | |
| Esperion Therapeutics, INC. | $16.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.20 | 2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $16.13 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.78 | 2022 | |
| Inari Medical, INC. | $14.84 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Edwards Lifesciences Corporation | $14.44 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.17 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dudley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.